Non-Drug Blood Pressure-Lowering Device now Available in West Coast Stores of Third Largest Pharmacy Chain in the U.S.
New York, N.Y. — March 2, 2009—InterCure Ltd., a medical device company publicly traded on the Tel-Aviv Stock Exchange (TASE: INCR), today announced that its RESPeRATE® hypertension treatment device, clinically-proven to significantly lower blood pressure, will be sold in more than 800 Rite Aid retail stores throughout the West Coast.
High blood pressure affects approximately 72 million people in the United States and approximately one billion worldwide. Traditional treatment methods of diet, exercise and medication are often unable to help 70 percent of patients reach their lower blood pressure goals. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.
No one therapy fits all patients, and by offering this latest treatment option, Rite Aid demonstrates its commitment to its customers’ healthcare needs in the battle against a deadly and prevalent condition.
RESPeRATE® is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically-proven to lower blood pressure through paced breathing therapy. The device uses the body’s natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a “therapeutic zone” of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure Ltd. and RESPeRATE
InterCure Ltd. (Tel-Aviv Stock Exchange: INCR) is disrupting the $42 billion hypertension industry with the world’s first FDA-cleared, OTC blood pressure treatment device, RESPeRATE® (www.resperate.com). In a market where seven out of 10 hypertensives are NOT controlled despite the availability of more than 100 blood pressure medications, RESPeRATE provides an effective adjunctive non-drug therapy with no side effects.
RESPeRATE has gained widespread support of hypertension specialists and has secured regulatory clearance in most key international markets. Ten separate clinical studies have proven the device’s efficacy and safety, and RESPeRATE is now featured in more than 20 popular and professional text books.
With more than 100,000 units sold, thousands of supportive clinicians worldwide and one of the world’s most popular hypertension websites, InterCure is now introducing RESPeRATE into retail pharmacies to increase access to hypertension sufferers.
InterCure has an exciting product pipeline based on its broadly-patented “Device-Guided Breathing” technology platform. This technology enables a systematic reduction in sympathetic outflow of the autonomic nervous system, one of the key underlying causes of cardiovascular disease, insomnia and several other medical conditions.
Forward-Looking Statements
This news release may contain forward-looking statements that are based on the Company’s current beliefs and assumptions and on information currently available to its management. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. As a result of these risks, uncertainties and other factors, readers are cautioned not to place undue reliance on any forward-looking statements included in this press release. These forward-looking statements represent beliefs and assumptions only as of the date of this news release, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.
Contacts:
Lisa Mokaba
Schwartz Communications
781-684-0770
intercure@schwartz-pr.com
Brian Packard
InterCure, Inc.
646-652-5800 x 7134
bpackard@intercure.com